Madness in Medicine: Psychotic experiences and innovative approaches to mental health care in the UK
In plain English
AI plain-English summaryPsychedelic therapy trials exclude people with a history of psychosis, even though the drugs themselves can trigger psychotic-like experiences. This project investigates that contradiction. The researcher will embed in NHS clinics—both conventional psychosis wards and experimental psychedelic therapy settings—to observe how clinicians and patients define a “safe” or “therapeutic” psychotic experience in each context. The problem is that two rapidly evolving fields are talking past each other: psychedelic research treats psychotic experiences as potentially healing, while mainstream psychiatry treats them as dangerous and stigmatising. This gap leaves a highly disadvantaged group—people with psychosis, who are disproportionately from racialised and low-income communities—excluded from innovative treatments. If the research succeeds, it could reshape how mental health policy defines safety and efficacy. It may help destigmatise psychotic experiences and inform more equitable trial designs that do not automatically exclude people with psychosis. This is fundamental social science: it will not produce a new drug or device, but it could change the assumptions that underpin how such treatments are developed and who gets access to them.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Early-Career AwardPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know